Tom Brundage

Tom Brundage joined Chimerix in 2012 and was named Vice President of Biostatistics in 2021. He has over 25 years of development experience leading the study design, data collection, analysis, reporting, and submission activities for clinical trials across Phases I to IV. Prior to joining Chimerix, Mr. Brundage served in roles of increasing responsibility at Schering-Plough, Stiefel, and GlaxoSmithKline. He has been a key contributor to the development of numerous successful products throughout his career, including Noxafil®, Olux-E®, and Tembexa®. Mr. Brundage earned his BSE in Biomedical Engineering from Duke University and his MS in Statistics from Rutgers University.

Categorised in:

This post was written by tbe_admin